Sorin is now LivaNova. Learn more here

  • EN
  • IT

Company Factsheet

  • EN
  • IT

global medical device company


Every year, over 1,000,000 patients in more than 100 countries are treated with devices from Sorin Group.



For further information, please visit the About us section.

leader in the treatment of cardiovascular diseases

Focused on two major therapeutic areas:

Cardiac Surgery:  Cardiopulmonary products for open heart surgery and heart valve repair or replacement products

Cardiac Rhythm Management: Pacemakers, defibrillators, cardiac resynchronization devices.

Facts & Figures:

2014 Revenues: Euro 746.9m

Headquarters: Milan, Italy

Stock Exchange: Italian Stock Exchange (Borsa Italiana)

Ticker: Reuters SORN.MI; Bloomberg SRN IM

Employees: 3,900

Global reach: Manufacturing and R&D facilities in Brazil, Canada, China, the Dominican Republic, France, Germany, Italy and the United States.

Focus on R&D: 80 million Euro of R&D expenses (10% of revenues) in 2014 and over 500 dedicated employees

recent achievements:

  • Key product launches in Cardiac Surgery: Inspire-Heartlink-Connect system, Perceval, CROWN PRT
  • Key product launches in CRM: SonR, Reply 200, Kora 100
  • Acquisition of Alcard, Brazilian leading player in heart-lung machines
  • Acquisition of Oscor leads business, including manufacturing facility in the Dominican Republic
  • Greenfield project for cardiopulmonary products in China
  • Joint venture with MicroPort to enter the CRM Chinese market
  • Investment in Respicardia, developer of implantable therapies to improve Respiratory Rhythm Management
  • Continuous investments in the New Ventures growth platform


Investment highlights

  • Global leader in cardiopulmonary
  • Market leading positions in heart valves
  • Continuous geographic expansion
  • Robust R&D pipeline
  • New Ventures growth platforms
  • Committed to accelerate long-term growth


Version unknown | Revision 110938 | Status unstable | SessionId 79B2AFD7B5E3021FA7D764043D35D73B.jvm0